CN Patent

CN102834388A — Cgrp受体拮抗剂

Assigned to Bristol Myers Squibb Co · Expires 2012-12-19 · 13y expired

What this patent protects

本发明一般地涉及式I化合物，(R)-N-(3-(7-甲基-1H-吲唑-5-基)-1-(4-(1-甲基哌啶-4-基)哌嗪-1-基)-1-氧代丙-2-基)-4-(2-氧代-1,2-二氢喹啉-3-基)哌啶-1-甲酰胺，包括可药用盐，其为CGRP-受体拮抗剂。本发明还涉及药物组合物和在治疗CGRP相关障碍中使用所述化合物的方法，所述障碍包括偏头痛、神经性血管舒张、神经性炎症、热损伤、循环性休克、与绝经相关的潮红、气道炎性疾病如哮喘、慢性阻塞性肺病(COPD)和癌症。

USPTO Abstract

本发明一般地涉及式I化合物，(R)-N-(3-(7-甲基-1H-吲唑-5-基)-1-(4-(1-甲基哌啶-4-基)哌嗪-1-基)-1-氧代丙-2-基)-4-(2-氧代-1,2-二氢喹啉-3-基)哌啶-1-甲酰胺，包括可药用盐，其为CGRP-受体拮抗剂。本发明还涉及药物组合物和在治疗CGRP相关障碍中使用所述化合物的方法，所述障碍包括偏头痛、神经性血管舒张、神经性炎症、热损伤、循环性休克、与绝经相关的潮红、气道炎性疾病如哮喘、慢性阻塞性肺病(COPD)和癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN102834388A
Jurisdiction
CN
Classification
—
Expires
2012-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.